FDA Breakthrough Device Designation was granted to an AI-powered H&E-based prognostic assay for bladder cancer, described as the first such designation in this disease setting. Proprietary foundation ...

High-powered holmium and thulium laser platforms are expanding ureteroscopic options for complex patients, including those on anticoagulation, while emerging technologies such as Break Wave ...

Stacy Loeb, MD, MSc, discusses a study evaluating levels of at microplastics and nanoplastics in prostate cancer tissue. Loeb explained that her interest in this work was sparked by a study published ...

VYBRIQUE is a sildenafil oral film formulated for discreet, water-free administration, aiming to reduce use barriers for patients for whom privacy and convenience influence ED treatment adherence. A ...

"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.

Experts recommend removing unsupported prostate cancer warnings from TRT labels and aligning indications with professional guidelines. Testosterone's Schedule III classification creates barriers to ...

Panelists discuss how real-world comparisons of apalutamide and enzalutamide suggest survival trends influenced by tolerability, adherence, and patient selection rather than intrinsic drug differences ...

CaverSTIM is an investigational device for ED post prostatectomy, implanted during surgery to restore erectile function via neuromodulation. The pilot study at Johns Hopkins University will enroll 20 ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

Nocturnal enuresis affects millions, including adolescents and adults, and is not the child's fault but a sleep-related condition outside conscious control. Current treatments, including behavioral ...

"As with all medications and services, it is important to check with the patient’s insurer to determine their policy and whether the medication will be covered," write Jonathan Rubenstein, MD, and ...

Darolutamide plus ADT significantly improved radiographic progression-free survival in mHSPC patients, reducing the risk of progression or death by 46%. The ARANOTE trial showed no statistically ...